Dr Sana Al Sukhun speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the use of ovarian ablation for premenopausal patients with breast cancer.

She explains that this population of patients make up approximately 45 percent of breast cancer patients in the Middle East, compared to 10-15 percent seen in Western countries.

Dr Al Sukhun mentions that this type of targeted therapy can have a significant impact on hormone-dependent tumours and details which type of patients may benefit from this type of therapy.